دورية أكاديمية

The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry.

التفاصيل البيبلوغرافية
العنوان: The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry.
المؤلفون: Fajgenbaum, David C., Pierson, Sheila K., Kanhai, Karan, Bagg, Adam, Alapat, Daisy, Lim, Megan S., Lechowicz, Mary Jo, Srkalovic, Gordan, Uldrick, Thomas S., van Rhee, Frits
المصدر: British Journal of Haematology; Jul2022, Vol. 198 Issue 2, p307-316, 10p
مصطلحات موضوعية: CASTLEMAN'S disease, DISEASE progression, LYMPHOPROLIFERATIVE disorders, IMMUNOGLOBULIN M, LYMPHOCYTE count, MYELOFIBROSIS
مستخلص: Summary: Castleman disease (CD) describes a group of rare, potentially fatal lymphoproliferative disorders. To determine factors associated with mortality in CD, we analysed data from deceased patients in the ACCELERATE registry and compared them with matched controls. We analysed demographic, treatment and laboratory data from all deceased CD patients, matched controls and a subgroup of idiopathic multicentric Castleman disease (iMCD) patients. Of the 140 patients in ACCELERATE with a confirmed CD diagnosis, 10 had died. There were 72 patients with confirmed iMCD; six were deceased. The deceased CD cohort had more hospitalisations per year, higher overall hospitalisations and more days hospitalised per month, and received more treatment regimens per year than the matched‐control group. Analysis of laboratory values showed a significantly decreased absolute lymphocyte count at months 3 and 6 in the deceased cohort compared with controls. Among iMCD patients, there was a higher proportion of iMCD‐TAFRO (thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction and organomegaly) cases in the deceased group. The deceased iMCD group had significantly lower immunoglobulin M, international normalised ratio and platelet count. These data demonstrate that there may be differences between patients who have fatal and non‐fatal outcomes, and provide preliminary suggestions for parameters to evaluate further. [ABSTRACT FROM AUTHOR]
Copyright of British Journal of Haematology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:00071048
DOI:10.1111/bjh.18214